Dr. Miguel Burnier has been appointed the Interim Executive Director and Chief Scientific Officer of the Research Institute of the McGill University Health Centre (RI-MUHC)

Dr. Miguel Burnier has been appointed the Interim Executive Director and Chief Scientific Officer of the Research Institute of the McGill University Health Centre (RI-MUHC), beginning on June 15, 2020. In this capacity Dr. Burnier will work closely with RI-MUHC, MUHC and McGill leaders, as well as each of the MUHC associated foundations, to ensure continuity in the Institute’s research activities. In announcing his appointment, the Board of Directors emphasized his outstanding career in basic and translational research, his exceptional contributions to patient care, and his pioneering role as the founder and Director of the MUHC-McGill Ocular Pathology Translational Research Laboratory—the largest such research and training centre in North America, educating basic scientists, clinical pathologists, ophthalmologists, oncologists, medical students, residents and fellows from around the world. For details please see the article at https://rimuhc.ca/message-from-the-executive-director.

The Board of Directors of the Research Institute of the McGill University Health Centre (RI-MUHC)  announced the appointment of Dr. Miguel N. Burnier, Jr. to the position of Interim Executive Director and Chief Scientific Officer of the RI-MUHC. He succeeds Dr. Bruce Mazer, to whom the Board extends its deepest gratitude for having not only served in this capacity since fall 2016 but also graciously agreed to extend his term.

With this appointment, Dr. Burnier will work closely with RI-MUHC, MUHC and McGill leaders, as well as each of our associated foundations, to ensure continuity in the Institute’s research activities as a search for an Executive Director and Chief Scientific Officer is conducted.

Congratulations to Dr. Burnier!